EGFR and non-small cell lung carcinoma: The findings of this nonrandomized clinical trial suggest that high-dose aumolertinib treatment is associated with long survival benefit in patients with untreated EGFR-variant metastatic NSCLC and brain metastases, with a manageable safety profile.